Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Update on Chronic Lung Allograft Dysfunction.

Gauthier JM, Hachem RR, Kreisel D.

Curr Transplant Rep. 2016 Sep;3(3):185-191. doi: 10.1007/s40472-016-0112-y. Epub 2016 Aug 2.

2.

Sequelae of Donor-derived Mollicutes Transmission in Lung Recipients.

Fernandez R, Chi M, Ison MG, Waites KB, Crabb DM, Ratliff AE, Cajigas H, DeCamp MM, Odell D, Budinger GR, Bharat A.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):687-689. doi: 10.1164/rccm.201607-1377LE. No abstract available.

PMID:
27925760
3.

How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Williams KM.

Blood. 2017 Jan 26;129(4):448-455. doi: 10.1182/blood-2016-08-693507. Epub 2016 Nov 16. Review.

4.

Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.

Amer EI, Eissa MM, Mossallam SF.

J Parasit Dis. 2016 Jun;40(2):475-84. doi: 10.1007/s12639-014-0529-0. Epub 2014 Aug 31.

5.
6.

Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ, Martin PJ, Storer BE, Inamoto Y, Chai X, Flowers ME, Lee SJ.

Biol Blood Marrow Transplant. 2016 Apr;22(4):710-6. doi: 10.1016/j.bbmt.2015.10.009. Epub 2015 Oct 22.

7.

Immunosuppressive therapy in allograft transplantation: from novel insights and strategies to tolerance and challenges.

Ebrahimi A, Hosseini SA, Rahim F.

Cent Eur J Immunol. 2014;39(3):400-9. doi: 10.5114/ceji.2014.45955. Epub 2014 Oct 14. Review.

8.

A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation.

Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G, Johnson G, Ward C.

Thorax. 2015 May;70(5):442-50. doi: 10.1136/thoraxjnl-2014-205998. Epub 2015 Feb 24.

9.

Post-infectious bronchiolitis obliterans in children: CT features that predict responsiveness to pulse methylprednisolone.

Yoon HM, Lee JS, Hwang JY, Cho YA, Yoon HK, Yu J, Hong SJ, Yoon CH.

Br J Radiol. 2015 May;88(1049):20140478. doi: 10.1259/bjr.20140478. Epub 2015 Feb 24.

10.

Bronchiolitis obliterans associated with Stevens-Johnson syndrome: a case report.

Park H, Ko YB, Kwon HS, Lim CM.

Yonsei Med J. 2015 Mar;56(2):578-81. doi: 10.3349/ymj.2015.56.2.578.

11.

Post-infectious bronchiolitis obliterans in children: a review of 42 cases.

Li YN, Liu L, Qiao HM, Cheng H, Cheng HJ.

BMC Pediatr. 2014 Sep 25;14:238. doi: 10.1186/1471-2431-14-238.

12.

Immunosuppression in lung transplantation.

Scheffert JL, Raza K.

J Thorac Dis. 2014 Aug;6(8):1039-53. doi: 10.3978/j.issn.2072-1439.2014.04.23. Review.

13.

Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.

Weigt SS, DerHovanessian A, Wallace WD, Lynch JP 3rd, Belperio JA.

Semin Respir Crit Care Med. 2013 Jun;34(3):336-51. doi: 10.1055/s-0033-1348467. Epub 2013 Jul 2. Review.

14.

Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.

Banerjee B, Musk M, Sutanto EN, Yerkovich ST, Hopkins P, Knight DA, Lindsey-Temple S, Stick SM, Kicic A, Chambers DC.

PLoS One. 2012;7(12):e52309. doi: 10.1371/journal.pone.0052309. Epub 2012 Dec 21.

15.

Longitudinal analysis of the lung microbiome in lung transplantation.

Borewicz K, Pragman AA, Kim HB, Hertz M, Wendt C, Isaacson RE.

FEMS Microbiol Lett. 2013 Feb;339(1):57-65. doi: 10.1111/1574-6968.12053. Epub 2012 Dec 20.

16.

Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant.

Charlson ES, Diamond JM, Bittinger K, Fitzgerald AS, Yadav A, Haas AR, Bushman FD, Collman RG.

Am J Respir Crit Care Med. 2012 Sep 15;186(6):536-45. doi: 10.1164/rccm.201204-0693OC. Epub 2012 Jul 12.

17.

Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Steel HC, Theron AJ, Cockeran R, Anderson R, Feldman C.

Mediators Inflamm. 2012;2012:584262. doi: 10.1155/2012/584262. Epub 2012 Jun 21. Review.

18.

Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V, Emmett P, Marshall B, Accurso F, Sagel S, Anstead M.

Chest. 2012 Nov;142(5):1259-1266. doi: 10.1378/chest.12-0628.

19.

Azithromycin inhibits mucus hypersecretion from airway epithelial cells.

Shimizu T, Shimizu S.

Mediators Inflamm. 2012;2012:265714. doi: 10.1155/2012/265714. Epub 2012 Apr 23.

20.

Thin-section computed tomography findings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunction.

de Jong PA, Vos R, Verleden GM, Vanaudenaerde BM, Verschakelen JA.

Eur Radiol. 2011 Dec;21(12):2466-74. doi: 10.1007/s00330-011-2224-1. Epub 2011 Jul 27.

Supplemental Content

Support Center